VAB-6 as initial treatment of patients with advanced seminoma.

Abstract

Thirty patients with advanced seminoma were treated with VAB-6. Eighteen patients were previously untreated, eight had relapsed after radiation therapy, and four had persistent disease following chemotherapy and radiation therapy. Two patients had received prior high-dose cisplatin. Twenty-four (86%) of 28 evaluable patients achieved a complete remission. Four patients had relapsed. The median disease-free follow-up of patients achieving complete remission was 32+ months. VAB-6 is effective treatment for patients with advanced seminoma, and chemotherapy is recommended as the initial therapy in all patients with stage II seminoma with disease larger than 5 cm, extragonadal seminoma, and stage III seminoma.

• Authors: G F Stanton, G J Bosl, W F Whitmore Jr, H Herr, P Sogani, M Morse, R B Golbey
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 3 Issue 3 Pg. 336-9 (Mar 1985) ISSN: 0732-183X [Print] United States
• PMID: 2579214 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Bleomycin
• Chlorambucil
• Dactinomycin
• Vinblastine
• Doxorubicin
• Cyclophosphamide
• Cisplatin

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bleomycin (administration & dosage, adverse effects)
• Chlorambucil (administration & dosage, adverse effects)
• Cisplatin (administration & dosage, adverse effects)
• Cyclophosphamide (administration & dosage, adverse effects)
• Dactinomycin (administration & dosage, adverse effects)
• Doxorubicin (administration & dosage, adverse effects)
• Dysgerminoma (drug therapy)
• Humans
• Male
• Mediastinal Neoplasms (drug therapy)
• Retroperitoneal Neoplasms (drug therapy)
• Testicular Neoplasms (drug therapy)
• Vinblastine (administration & dosage, adverse effects)